LALCA 2016

Lalca banner

The 7th Latin American Conference on Lung Cancer (LALCA) took place on 25–27 August 2016 at the Riu Plaza Panama, Panama City, Panama. LALCA was hosted by the International Association for the Study of Lung Cancer (IASLC).

Boehringer Ingelheim hosted a satellite symposium entitled, ‘Treatment updates in NSCLC: Translating evidence into clinical practice’. The meeting was chaired by Prof. Carlos Silva, and included presentations given by Prof. Oscar Gerardo Arrieta Rodríguez and Dr Noemí Reguart.

Of special note, there was a poster discussion on the impact of dose adjustment on afatinib safety and efficacy in EGFR mutation-positive NSCLC.

For more details see below.

The full LALCA programme can be found here.

LALCA 2016 Industry symposium

Treatment updates in NSCLC: Translating evidence into clinical practice

Friday 26 August, 13:30–14:30


Prof. Carlos Silva
Argentinan Catholic University, Buenos Aires, Argentina


Prof. Oscar Gerardo Arrieta Rodríguez
National Cancer Institute Mexico City, Mexico
Dr Noemí Reguart
Hospital Clinic Barcelona
Barcelona, Spain


13:30 – 13:40

Welcome, introductions and opening presentation

Carlos Silva

13:40 – 14:10

Treatment considerations for first-line EGFR M+ NSCLC: irreversible ErbB Family blockade

Noemí Reguart

14:10 – 14:25

Anti-angiogenic inhibition in NSCLC: From trial to practice

Oscar Gerardo Arrieta Rodríguez

14:25 – 14:30

Final questions, summary and meeting close

Carlos Silva

Click here to view the invitation


Click here to view the book of abstracts